Real-world analysis of treatment patterns examining nab-Paclitaxel plus gemcitabine (nab-P+G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting.

Fadi S. Braiteh,Manish Patel,Monika Parisi,Quanhong Ni,Si yeon Park,Claudio Faria

Real-world analysis of treatment patterns examining nab-Paclitaxel plus gemcitabine (nab-P+G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting.

2016

Fadi S. Braiteh
Manish Patel
Monika Parisi
Quanhong Ni
Si yeon Park
Claudio Faria

e18100Background: Based on a randomized clinical trial, MPACT, nab-P+G had superior overall survival (OS) compared to G for the treatment of advanced PAC, but limited data is available comparing th...

Keywords:

Nab-paclitaxel
Metastatic Pancreatic Adenocarcinoma
Gemcitabine
Oncology
Internal medicine
Medicine
overall survival
first line treatment
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations